Link: https://links.sgx.com/1.0.0/corporate-announcements/3JNVXIMWL9N67LWS/8ad34df5dea633bd767b5c3abbc7dcac6f7d41b3df482751c5a31131faf08566

Summary:

• Revenue:

  • Q2 2025: RM 6,298 million (+3% YoY)

  • H1 2025: RM 12,592 million (+5% YoY)

• Profit After Tax:

  • Q2 2025: RM 567 million (-24%)

  • H1 2025: RM 1,192 million (-29%)

• Net Profit Attributable to Owners:

  • Q2 2025: RM 443 million (-29%)

  • H1 2025: RM 957 million (-31%)

  • Basic EPS: 10.85 sen (H1 2024: 15.79 sen)

• Dividend: Interim dividend of 5.0 sen per share (up from 4.5 sen), declared for H1 2025.

• Net Assets per Share: RM 3.45 (up from RM 3.42 at end-2024)

• Drivers/Key Moves:

  • Revenue rose on continued demand, more acute cases, new hospital consolidation (Island Hospital), and higher prices to offset inflation.

  • Profit fell on higher staff, depreciation, and interest costs, increased forex translation/hedging costs (mainly Turkey).

  • Net assets and total equity increased slightly.

  • Strong cash and cash equivalents: RM 1.53 billion

  • Loans and borrowings stood at RM 13.57 billion (up due to expansion, equipment).

• Segment/Geography:

  • Revenue growth across all major markets: Malaysia (+16%), Singapore (-2%), China (+5%), India (+2%), Turkiye/Europe (+14%).

  • EBITDA positive across all hospital regions, led by Malaysia and Turkiye/Europe.

• Balance Sheet:

  • Total assets: RM 56.83 billion

  • Equity: RM 34.25 billion

• Subsequent Notable Events: Acquisition of Turkish hospital group Bayindir (July 2025), expansion of India network with a major new hospital.

Outlook: IHH expects revenue growth to continue with ongoing expansions, but is mindful of cost pressures, FX volatility (especially in Turkey), and will continue to prioritize operational efficiency and prudent capital management.